OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, et al.
Patient Preference and Adherence (2022) Vol. Volume 16, pp. 615-624
Open Access | Times Cited: 7
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, et al.
Patient Preference and Adherence (2022) Vol. Volume 16, pp. 615-624
Open Access | Times Cited: 7
Showing 7 citing articles:
An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder
Justin Faden, Camila Ramirez, Vanessa Sánchez Martínez, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 8, pp. 761-771
Closed Access | Times Cited: 6
Justin Faden, Camila Ramirez, Vanessa Sánchez Martínez, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 8, pp. 761-771
Closed Access | Times Cited: 6
Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
Giuseppe Cicala, Renato de Filippis, María Antonietta Barbieri, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 9
Giuseppe Cicala, Renato de Filippis, María Antonietta Barbieri, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 9
Invega Hafyera (Paliperidone Palmitate): Extended-Release Injectable Suspension for Patients With Schizophrenia
Lindsey Peters, Megan Dyer, Emily B. Schroeder, et al.
Journal of Pharmacy Technology (2023) Vol. 39, Iss. 2, pp. 88-94
Closed Access | Times Cited: 8
Lindsey Peters, Megan Dyer, Emily B. Schroeder, et al.
Journal of Pharmacy Technology (2023) Vol. 39, Iss. 2, pp. 88-94
Closed Access | Times Cited: 8
Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety
Joshua Barnett, Sofia Pappa
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 1603-1610
Open Access | Times Cited: 7
Joshua Barnett, Sofia Pappa
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 1603-1610
Open Access | Times Cited: 7
The development of paliperidone nanocrystals for the treatment of schizophrenia
Phattalapol Lhaglham, Luksika Jiramonai, Xing‐Jie Liang, et al.
Progress in Biomedical Engineering (2024) Vol. 7, Iss. 1, pp. 012002-012002
Closed Access | Times Cited: 1
Phattalapol Lhaglham, Luksika Jiramonai, Xing‐Jie Liang, et al.
Progress in Biomedical Engineering (2024) Vol. 7, Iss. 1, pp. 012002-012002
Closed Access | Times Cited: 1
Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
Juan Antonio García-Carmona, Sofia Pappa
Drug Healthcare and Patient Safety (2023) Vol. Volume 15, pp. 113-123
Open Access | Times Cited: 3
Juan Antonio García-Carmona, Sofia Pappa
Drug Healthcare and Patient Safety (2023) Vol. Volume 15, pp. 113-123
Open Access | Times Cited: 3
